Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.

Journal

Bone marrow transplantation

ISSN: 1476-5365

Titre abrégé: Bone Marrow Transplant

Pays: England

ID NLM: 8702459

Informations de publication

Date de publication:
07 Oct 2024

Historique:

received: 06 08 2024

accepted: 26 09 2024

revised: 24 09 2024

medline: 8 10 2024

pubmed: 8 10 2024

entrez: 7 10 2024

Statut: aheadofprint

Résumé

Autologous peripheral blood stem cell (PBSC) transplantation is a standard treatment of multiple myeloma (MM), Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma. Cryopreservation of hematopoietic stem cells is standard practice that allows time for delivery of conditioning regimen prior to cell infusion. The aim of this Worldwide Network for Blood & Marrow Transplantation (WBMT) work was to assess existing evidence on non-cryopreserved autologous transplants through a systematic review/meta-analysis, to study feasibility and safety of this approach. We searched PubMed, Web of Science and SCOPUS for studies that utilized non-cryopreserved autologous PBSC transplantation. Identified literature was reviewed for information on mobilization, apheresis, preservation and viability, conditioning regimen, engraftment, response, and survival. Results highlight collective experience from 19 transplant centers (1686 patients), that performed autologous transplants using non-cryopreserved PBSCs. The mean of infused CD34+ was 5.6 × 10

Identifiants

DOI: 10.1038/s41409-024-02431-y PMID: 39375527

pubmed: 39375527

doi: 10.1038/s41409-024-02431-y

pii: 10.1038/s41409-024-02431-y

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Kessinger A, Armitage JO, Landmark J, Weisenburger D. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol. 1986;14:192–6.

pubmed: 2868909

Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. 1988;71:723–7.

Abdrabou AK, Sharif FA, Fakih RE, Hashmi S, Khafaga YM, Alhayli S, et al. Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia. Ann Saudi Med. 2021;41:198–205.

doi: 10.5144/0256-4947.2021.198 pubmed: 34420396 pmcid: 8380276

Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107:1045.

doi: 10.3324/haematol.2021.279189 pubmed: 34382386

Fermand J-P, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227–33.

doi: 10.1200/JCO.2005.03.0551 pubmed: 16275936

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5.

doi: 10.1056/NEJM199512073332305 pubmed: 7477169

André M, Henry-Amar M, Pico J-L, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. J Clin Oncol. 1999;17:222.

doi: 10.1200/JCO.1999.17.1.222 pubmed: 10458237

Carella AM, Bellei M, Brice P, Gisselbrecht C, Visani G, Colombat P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results. Haematologica. 2009;94:146.

doi: 10.3324/haematol.13484 pubmed: 19001284

Gorin N. Collection, manipulation and freezing of haemopoietic stem cells. Clin Haematol. 1986;15:19–48.

doi: 10.1016/S0308-2261(86)80004-2 pubmed: 2870831

Billen D. Recovery of lethally irradiat-ed mice by treatment with bone marrow cells maintained in vitro. nature1957;179:574–5.

Ahmed T, Wuest D, Ciavarella D, Ayello J, Feldman EJ, Biguzzi S, et al. Marrow storage techniques: a clinical comparison of refrigeration versus cryopreservation. Acta Haematol. 1991;85:173–8.

doi: 10.1159/000204886 pubmed: 1906669

Sierra J, Conde E, Iriondo A, Brunet S, Marin J, de Oteiza JP, et al. Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: a report from the Spanish GEL/TAMO Cooperative Group. Ann Hematol. 1993;67:111–4.

doi: 10.1007/BF01701731 pubmed: 8373895

Preti R, Razis E, Ciavarella D, Fan Y, Kuhns R, Cook P, et al. Clinical and laboratory comparison study of refrigerated and cryopreserved bone marrow for transplantation. Bone Marrow Transplant. 1994;13:253–60.

pubmed: 8199568

Hechler G, Weide R, Heymanns J, Köppler H, Havemann K. Storage of noncryopreserved periphered blood stem cells for transplantation. Ann Hematol. 1996;72:303–6.

doi: 10.1007/s002770050176 pubmed: 8645742

Wannesson L, Panzarella T, Mikhael J, Keating A. Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. Ann Oncol. 2007;18:623–32.

doi: 10.1093/annonc/mdm069 pubmed: 17355952

Al-Anazi KA. Autologous hematopoietic stem cell transplantation for multiple myeloma without cryopreservation. Bone Marrow Res. 2012;2012:917361.

Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M. et al. The NewcastleOttawa Scale (NOS) for assessing the quality if nonrandomized studies in metaanalyses. Ontario, Canada. 2024. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp .

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–14.

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

doi: 10.1186/1471-2288-14-135 pubmed: 25524443 pmcid: 4383202

Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21:607–11.

Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67:974–8.

Lewis S, Clarke MJB. Forest plots: trying to see the wood and the trees. 2001;322:1479–80.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. 2003;327:557–60.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.

Papadimitriou CA, Dimopoulos MA, Kouvelis V, Kostis E, Kapsimali V, Contoyannis D, et al. Non‐cryopreserved peripheral blood progenitor cells collected by a single very large‐volume leukapheresis: a simplified and effective procedure for support of high‐dose chemotherapy. J Clin Apher. 2000;15:236–41.

doi: 10.1002/1098-1101(2000)15:4<236::AID-JCA4>3.0.CO;2-R pubmed: 11124691

Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Ruiz-Argüelles A, Pérez-Romano B, Rivadeneyra L. Results of an autologous noncryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: a single-institution, 10-year experience. Acta Haematol. 2003;110:179–83.

doi: 10.1159/000074221 pubmed: 14663161

Cuellar-Ambrosi F, Karduss U, Gomez W, Mondragon M, Velasquez-Lopera M, Calle S, editors. Hematologic reconstitution following high-dose and supralethal chemoradiotherapy using stored, noncryopreserved autologous hematopoietic stem cells. Transplantation Proc. 2004;36:1704–5.

Mabed M, Shamaa S. High-dose chemotherapy plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed Hodgkin disease. Biol Blood Marrow Transpl. 2006;12:942–8.

doi: 10.1016/j.bbmt.2006.05.013

Mabed M, Al-Kgodary T. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin’s lymphomas. Bone marrow Transplant. 2006;37:739–43.

doi: 10.1038/sj.bmt.1705314 pubmed: 16501587

López-Otero A, Ruiz-Delgado G, Ruiz-Argüelles G. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant. 2009;44:715–9.

doi: 10.1038/bmt.2009.71 pubmed: 19349952

Ramzi M, Zakerinia M, Nourani H, Dehghani M, Vojdani R, Haghighinejad H. Non‐cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience. Clin Transplant. 2012;26:117–22.

doi: 10.1111/j.1399-0012.2011.01432.x pubmed: 21919958

Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transpl. 2012;10:163–7.

doi: 10.6002/ect.2011.0092

Bekadja M-A, Brahimi M, Osmani S, Arabi A, Bouhass R, Yafour N, et al. A simplified method for autologous stem cell transplantation in multiple myeloma. Hematol Oncol Stem Cell Ther. 2012;5:49–53.

doi: 10.5144/1658-3876.2012.49 pubmed: 22446610

Kayal S, Sharma A, Iqbal S, Tejomurtula T, Cyriac SL, Raina V. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells. Clin Lymphoma Myeloma Leuk. 2014;14:140–7.

doi: 10.1016/j.clml.2013.09.001 pubmed: 24342104

Bekadja MA, Brahimi M, Osmani S, Yafour N, Krim A, Serradj F, et al. Hematopoietic stem cell transplantation in Algeria. Hematol Oncol Stem Cell Ther. 2017;10:311–4.

doi: 10.1016/j.hemonc.2017.05.019 pubmed: 28711452

Sarmiento M, Ramírez P, Parody R, Salas M, Beffermann N, Jara V, et al. Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy. Bone Marrow Transplant. 2018;53:960–6.

doi: 10.1038/s41409-018-0117-5 pubmed: 29440738

Kardduss-Urueta A, Gale RP, Gutierrez-Aguirre CH, Herrera-Rojas MA, Murrieta-Álvarez I, Perez-Fontalvo R, et al. Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. Bone Marrow Transpantl. 2018;53:457–60.

doi: 10.1038/s41409-017-0047-7

Naithani R, Dayal N, Pathak S, Rai R. Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma. Bone Marrow Transplant. 2018;53:1198–200.

doi: 10.1038/s41409-018-0174-9 pubmed: 29599528

Kulkarni U, Devasia AJ, Korula A, Fouzia N, Nisham P, Samoon YJ, et al. Use of non-cryopreserved peripheral blood stem cells is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant. Biol Blood Marrow Transplant. 2018;24:e31–5.

doi: 10.1016/j.bbmt.2018.08.007 pubmed: 30142418

Bittencourt M, Mariano L, Moreira F, Schmidt-Filho J, Mendrone-Jr A, Rocha V. Cryopreserved versus non-cryopreserved peripheral blood stem cells for autologous transplantation after high-dose Melphalan in multiple myeloma: comparative analysis. Bone marrow Transplant. 2019;54:138–41.

doi: 10.1038/s41409-018-0250-1 pubmed: 30108325

Jennane S, Hasnaoui N, Mahtat E, Merimi F, Bougar S, El Maaroufi H, et al. Non-cryopreserved peripheral blood stem cells autologous transplantation in multiple myeloma: bicentric study. Transfus Clin Biol. 2020;27:152–6.

doi: 10.1016/j.tracli.2020.03.006 pubmed: 32334934

Piriyakhuntorn P, Tantiworawit A, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E. et al. Outcomes of non-cryopreserved versus cryopreserved peripheral blood stem cells for autologous stem cell transplantation in multiple myeloma. Ann Transplant. 2020;25:e927084-1–7.

doi: 10.12659/AOT.927084

Bekadja M-A, Boumendil A, Blaise D, Chevallier P, Peggs KS, Salles G, et al. Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. Cytotherapy. 2021;23:483–7.

doi: 10.1016/j.jcyt.2020.12.016 pubmed: 33678598

Fleming K, Hubel A. Cryopreservation of hematopoietic and non-hematopoietic stem cells. Transfus Apheresis Sci. 2006;34:309–15.

doi: 10.1016/j.transci.2005.11.012

Lobo F, Kessinger A, Landmark J, Smith D, Weisenburger D, Wigton R, et al. Addition of peripheral blood stem cells collected without mobilization techniques to transplanted autologous bone marrow did not hasten marrow recovery following myeloablative therapy. Bone marrow Transplant. 1991;8:389–92.

pubmed: 1685105

Smith R, Sweetenham J. A mononuclear cell dose of 3 x 10 (8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. Exp Hematol. 1995;23:1581–8.

pubmed: 8542950

Bekadja M, Talhi S, Amani K, Osmani S, Brahimi M, Mazari M, et al. Outcomes of modified-eam conditioned autologous non-cryopreserved hematopoietic sct for lymphoma. a retrospective single-centre study. Bone Marrow Transplant. 2018;53:1596–8.

doi: 10.1038/s41409-018-0243-0 pubmed: 29895930

Garifullin A, Voloshin S, Linnikov S, Kuzyaeva A, Balashova V, Chubukina Z. The use of non-cryopreserved and cryopreserved hematopoietic stem cells for autotransplantation in multiple myeloma. HemaSphere. 2021;5:494–5.

Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, et al. Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. Biol Blood Marrow Transplant. 2013;19:1670–6.

doi: 10.1016/j.bbmt.2013.08.005 pubmed: 23988403

Bekadja MA, Omani S, Talhi S, Brahimi M, Yafour N, Arabi A, et al. L’autogreffe de cellules souches périphériques (CSP) non cryopréservées dans les lymphomes de Hodgkin (LH). Expérience de I’EHU 1er novembre d’Oran. Revue Algérienne d’Hématologie. 2015;10-11:40-45